🇺🇸 FDA
Pipeline program

Tozorakimab

D9185C00001

Phase 3 small_molecule active

Quick answer

Tozorakimab for Viral Lung Infection and Acute Respiratory Failure is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Viral Lung Infection and Acute Respiratory Failure
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials